David Rosmarin, MD: Efficacy of Ruxolitinib Cream in Progressive and Stable Vitiligo

March 23, 2026

David Rosmarin, MD, the chair of the Department of Dermatology at Indiana University in Indianapolis, discusses results from a pooled subgroup analysis of the 104-week TRuE-V1 and TRuE-V2 phase 3 trials (NCT04052425, NCT04057573) evaluating repigmentation with ruxolitinib cream in patients with progressive vitiligo. The analysis, presented as a poster at the 2026 Winter Clinical Miami conference, included 440 patients, of whom 25% had progressive disease. Repigmentation outcomes were assessed using the Facial Vitiligo Area Scoring Index and Total Vitiligo Area Scoring Index at Weeks 24, 52, and 104. The data demonstrated no statistically significant differences in repigmentation between patients with progressive vs stable vitiligo. Adverse events and baseline characteristics were comparable between groups.

Topics Covered

Common signs of active vitiligo in patients
Safety and efficacy of ruxolitinib cream
Improvement in progressive and stable vitiligo over time

Explore Related Resources

MORE EXPERT PERSPECTIVES IN VITILIGO

Tristan Hasbargen, PA-C: Setting Expectations for a Long-Term Approach to Repigmentation

Tristan Hasbargen, PA-C, a physician assistant at Dermatology Associates of Tallahassee in Tallahassee, Florida, discusses the treatment of vitiligo, emphasizing the importance of setting patient

Seemal Desai, MD, FAAD: Providing Effective Treatment for Patients with Facial Vitiligo

Dr. Desai discusses treating patients with vitiligo with ruxolitinib cream 1.5% in the face and neck area.

Chantel Hillestad, RN, MSN, DCNP, FNP-C: Treating Patients with Vitiligo on the Hands

Chantel Hillestad discusses treatment options for vitiligo on the hands and how UV exposure can increase the presentation of vitiligo.

Chantel Hillestad, RN, MSN, DCNP, FNP-C: Restoring Pigmentation in Patients with Vitiligo

Chantel Hillestad, RN, MSN, DCNP, FNP-C, shares clinical experience using ruxolitinib to restore pigmentation in vitiligo patients across all age groups. Topics Covered: Ruxolitinib for

Seemal Desai, MD, FAAD: Assessing Efficacy of Ruxolitinib in Characteristic Subgroups for Patients with Vitiligo

Dr. Desai discusses the efficacy and longevity of treatment with ruxolitinib cream 1.5% in patients with facial vitiligo based on a recent post-hoc analysis of

Jennifer Silva, APRN-DNP: Safety Considerations for Treating Patients with Vitiligo

Jennifer Silva discusses the importance of discussing black box warnings when utilizing JAK inhibitors in patients with vitiligo.

Julien Seneschal, MD, PhD: An Update on Topical and Systemic JAK Inhibition for Vitiligo

Dr. Seneschal discusses currently available topical JAKs for vitiligo, systemic JAKs being trialed to treat the condition in the future, and how JAKs can be

Jennifer Silva, APRN-DNP: Providing Adequate Treatment for Patients with Vitiligo

Jennifer Silva, APRN-DNP, outlines treatment options for patients with vitiligo who have not responded well to traditional therapies. Topics Covered: Challenges in vitiligo treatment Strategies

Iltefat Hamzavi, MD: Combining Phototherapy with Topical Therapy in Patients with Vitiligo

Iltefat Hamzavi, MD, and JCAD’s Editor-in-Chief, James Del Rosso, DO, discuss topical treatment considerations for patients with vitiligo when using topical ruxolitinib cream, including topical

David Rosmarin, MD: Updates in Topical and Systemic Vitiligo Treatment

Dr. Rosmarin discusses his vitiligo session from November’s Masterclasses in Dermatology Meeting, in which he reviewed recent insights on maintaining and building upon initial treatment

Gina Mangin, MPAS, PA-C: Coaching Pearls for Patients with Vitiligo

Gina Mangin discusses effective treatment practice for patients with vitiligo centered around providing encouragement and motivation throughout the process.

Gina Mangin, MPAS, PA-C: Using Light Box Therapy for Patients with Vitiligo

Gina Mangin, MPAS, PA-C, discusses the role of light box therapy in vitiligo management, with a focus on setting clear expectations around treatment timelines and

Nada Elbuluk, MD: Psychological Comorbidity Assessment and Counseling for Patients with Vitiligo

Nada Elbuluk, MD, discusses the importance of assessing psychological comorbidities in patients with vitiligo by gathering key social information, including daily activities, living situation, and

Shanna Miranti, MPAS, PA-C: Prescribing Ruxolitinib for Patients with Vitiligo

Shanna Miranti, MPAS, PA-C, discusses prescribing considerations for topical ruxolitinib in patients with vitiligo, emphasizing the importance of prior treatment attempts with topical corticosteroids and

James Del Rosso, DO: Discussing Early Immune Activity Upon Ruxolitinib Cream Withdrawal

Dr. Del Rosso, JCAD’s Clinical Editor-in-Chief, reviews a poster presented by Volkova et al at the 2024 American Academy of Dermatology annual meeting. The poster

Shanna Miranti, MPAS, PA-C: Assessing Treatment Efficacy in Patients with Vitiligo

Shanna Miranti, MPAS, PA-C, discusses the similar efficacy seen in patients treated with ruxolitinib at diagnosis versus those who had disease for years.

Shanna Miranti, MPAS, PA-C: Managing the Psychosocial Impact of Vitiligo

Shanna Miranti, MPAS, PA-C, discusses the bimodal distribution of vitiligo in male and female individuals and the necessary counseling for those who are managing their

Nada Elbuluk, MD: Connecting Patients with Vitiligo with Supportive Resources

Dr. Elbuluk discusses the importance of connecting patients with vitiligo to supportive resources for preventing and mitigating anxiety and depression related to the condition, especially

Andrea Nguyen, PA-C, MS: Determining Treatment Goals and Expectations for Patients with Vitiligo

Andrea Nguyen discusses how she counsels patients with vitiligo and emphasizes the importance in communicating with patients about consistent application and dosing during a treatment

Nada Elbuluk, MD: New Research on Psychological Comorbidities in Patients with Vitiligo

Dr. Elbuluk discusses a recently published retrospective chart review that she and her colleagues published in the Archives of Dermatological Research, which included all patients

Raj Chovatiya, MD, PhD: Utilizing Ruxolitinib Cream for Patients with Vitiligo

Dr. Chovatiya discusses how to effectively treat patients with nonsegmental vitiligo using topical ruxolitinib cream and the importance in a slow and steady treatment regimen.

Nada Elbuluk, MD, FAAD: Research and Utility of Ruxolitinib Cream for Vitiligo

Dr. Elbuluk discusses results of the clinical trials for ruxolitinib cream in patients with vitiligo and how this treatment is being incorporated into the dermatologist’s

John Harris, MD, PhD: Effective Treatment for Patients with Vitiligo

John Harris, MD, PhD, Chair of Dermatology at UMass Chan Medical School, discusses the impact topical ruxolitinib cream has had on patients with vitiligo. He

Susan Taylor, MD: The Impact of Vitiligo on Patients of Color

Susan Taylor, MD, Professor of Dermatology at The University of Pennsylvania in Philadelphia, Pennsylvania, reviews the burden of vitiligo on patients of color and reviews

Nada Elbuluk, MD: Current and Future Treatment Options for Patients with Vitiligo

Nada Elbuluk, MD, a board certified dermatologist at the University of Southern California in Los Angeles, California, discusses the importance of offering a variety of

John Harris, MD, PhD: The Evolution of Treatments for Vitiligo

John Harris, MD, PhD, Chair of Dermatology at Umass Chan Medical School, reviews the history of treatments for vitiligo, current treatments for vitiligo and their

Pearl Grimes, MD: The Psychological Impact of Vitiligo and Advancements in Treatment

Pearl Grimes, MD, Director of of Vitiligo and Pigmentation Institute of Southern California and Clinical Professor of Dermatology at UCLA discusses exciting advancements in therapy

JCAD Archives